Rosetta Genomics Company Profile (NASDAQ:ROSG)

About Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics logoRosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ROSG
  • CUSIP: N/A
  • Web: www.rosettagenomics.com
Capitalization:
  • Market Cap: $3.21 million
  • Outstanding Shares: 1,868,000
Average Prices:
  • 50 Day Moving Avg: $2.36
  • 200 Day Moving Avg: $5.13
  • 52 Week Range: $1.40 - $18.60
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.43
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $9.23 million
  • Price / Sales: 0.35
  • Book Value: $2.40 per share
  • Price / Book: 0.72
Profitability:
  • EBIDTA: ($14,760,000.00)
  • Net Margins: -167.32%
  • Return on Equity: -127.01%
  • Return on Assets: -103.27%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 2.70%
  • Quick Ratio: 2.70%
Misc:
  • Average Volume: 131,461 shs.
  • Beta: -5.34
  • Short Ratio: 0.55
 

Frequently Asked Questions for Rosetta Genomics (NASDAQ:ROSG)

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."

How were Rosetta Genomics' earnings last quarter?

Rosetta Genomics Ltd. (NASDAQ:ROSG) released its quarterly earnings data on Thursday, May, 19th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.36 million. Rosetta Genomics had a negative net margin of 167.32% and a negative return on equity of 127.01%. View Rosetta Genomics' Earnings History.

Where is Rosetta Genomics' stock going? Where will Rosetta Genomics' stock price be in 2017?

2 analysts have issued 1-year price objectives for Rosetta Genomics' shares. Their forecasts range from $0.82 to $3.50. On average, they expect Rosetta Genomics' share price to reach $2.16 in the next year. View Analyst Ratings for Rosetta Genomics.

Who are some of Rosetta Genomics' key competitors?

Who owns Rosetta Genomics stock?

Rosetta Genomics' stock is owned by many different of institutional and retail investors. Top institutional investors include Morgan Stanley (3.34%). View Institutional Ownership Trends for Rosetta Genomics.

Who sold Rosetta Genomics stock? Who is selling Rosetta Genomics stock?

Rosetta Genomics' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Rosetta Genomics.

How do I buy Rosetta Genomics stock?

Shares of Rosetta Genomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rosetta Genomics stock cost?

One share of Rosetta Genomics stock can currently be purchased for approximately $1.72.

Analyst Ratings

Consensus Ratings for Rosetta Genomics (NASDAQ:ROSG) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.16 (25.58% upside)

Analysts' Ratings History for Rosetta Genomics (NASDAQ:ROSG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/6/2017AegisReiterated RatingBuy$3.50N/AView Rating Details
9/7/2016S&P Equity ResearchLower Price Target$0.94 -> $0.82N/AView Rating Details
6/13/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
3/28/2016Barrington ResearchLower Price TargetOutperform$5.00 -> $3.50N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Rosetta Genomics (NASDAQ:ROSG)
Earnings by Quarter for Rosetta Genomics (NASDAQ:ROSG)
Earnings History by Quarter for Rosetta Genomics (NASDAQ:ROSG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/26/2016Q216($0.17)($0.16)$2.89 million$2.41 millionViewListenView Earnings Details
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details
3/23/2016Q415($0.33)($0.14)$3.50 million$3.60 millionViewListenView Earnings Details
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
Current Year EPS Consensus Estimate: $-5.64 EPS
Next Year EPS Consensus Estimate: $-3.96 EPS

Dividends

Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Rosetta Genomics (NASDAQ:ROSG)
Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
Source:
DateHeadline
finance.yahoo.com logoRosetta Genomics Enters Collaboration to Develop a microRNA Classifier Relating to Patients with Non-Small Cell Lung Cancer Considered for Treatment with Immuno-oncology Drugs
finance.yahoo.com - May 23 at 9:34 AM
finance.yahoo.com logoRosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx Business and Monetizing IP
finance.yahoo.com - May 22 at 9:19 AM
finance.yahoo.com logoRosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM) and the Afirma GEC Assay for the Classification of Indeterminate Thyroid Nodules
finance.yahoo.com - May 12 at 10:52 PM
americanbankingnews.com logoZacks: Brokerages Set $34.01 Price Target for Rosetta Genomics Ltd. (ROSG)
www.americanbankingnews.com - May 8 at 11:28 AM
finance.yahoo.com logoRosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with Cytolog Laboratories in Brazil
finance.yahoo.com - May 5 at 8:09 AM
finance.yahoo.com logoRosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay
finance.yahoo.com - May 4 at 7:49 PM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Impact Rosetta Genomics (ROSG) Share Price
www.americanbankingnews.com - May 2 at 9:46 AM
finance.yahoo.com logoRosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives for the PersonalizeDx Business
finance.yahoo.com - May 2 at 9:45 AM
finance.yahoo.com logoRosetta Genomics Expands Patent Portfolio in Europe and Japan
finance.yahoo.com - May 1 at 10:09 AM
finance.yahoo.com logoNew Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary Thyroid Cancer to be Presented at the AACE 2017 Annual Meeting
finance.yahoo.com - April 27 at 10:59 AM
americanbankingnews.com logoRosetta Genomics (ROSG) Earning Very Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 22 at 7:47 AM
americanbankingnews.com logo Rosetta Genomics Ltd. (ROSG) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 21 at 7:31 AM
americanbankingnews.com logoVery Favorable Press Coverage Extremely Likely to Affect Rosetta Genomics (ROSG) Stock Price
www.americanbankingnews.com - April 18 at 10:23 AM
americanbankingnews.com logoZacks: Analysts Set $34.01 Target Price for Rosetta Genomics Ltd. (ROSG)
www.americanbankingnews.com - April 6 at 5:18 PM
finance.yahoo.com logoEdited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT
finance.yahoo.com - March 31 at 12:52 AM
finance.yahoo.com logoRosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 30 at 7:51 PM
biz.yahoo.com logoFull Year 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open
biz.yahoo.com - March 30 at 7:51 PM
americanbankingnews.com logoRosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 29 at 9:05 AM
finance.yahoo.com logoRosetta Genomics to Host 2016 Fourth Quarter and Year End Financial Results and Business Update Conference Call on March 30, 2017
finance.yahoo.com - March 23 at 8:20 AM
us.rd.yahoo.com logoRosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay
us.rd.yahoo.com - March 20 at 5:40 PM
streetinsider.com logoRosetta Genomics (ROSG) Reports Patent for its Unique RosettaGX Reveal Assay - StreetInsider.com
www.streetinsider.com - March 20 at 9:14 AM
biz.yahoo.com logoSplits Calendar: Rosetta Genomics splits before market open today (1:12 ratio)
biz.yahoo.com - March 17 at 7:40 PM
streetinsider.com logoRosetta Genomics (ROSG) 1-for-12 Reverse Stock Split Effective Tomorrow - StreetInsider.com
www.streetinsider.com - March 17 at 1:29 AM
us.rd.yahoo.com logo12:02 pm Rosetta Genomics announces 1:12 reverse stock split; will begin trading on a split-adjusted basis tomorrow at the open
us.rd.yahoo.com - March 16 at 8:27 PM
finance.yahoo.com logoRosetta Genomics Announces 1-for-12 Reverse Stock Split
finance.yahoo.com - March 16 at 8:27 PM
businesswire.com logoRosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures - Business Wire (press release)
www.businesswire.com - February 24 at 8:00 AM
finance.yahoo.com logoRosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures
finance.yahoo.com - February 23 at 7:46 PM
finance.yahoo.com logoRosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth Quarter and Year
finance.yahoo.com - February 8 at 11:30 PM
finance.yahoo.com logo8:03 am Rosetta Genomics: USPTO has granted two patents, both divisional patents of the parent application titled 'microRNAs and uses thereof'
finance.yahoo.com - February 6 at 7:41 PM
businesswire.com logoRosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx Reveal TM microRNAs
www.businesswire.com - February 6 at 8:43 AM
finance.yahoo.com logoRosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs
finance.yahoo.com - February 6 at 8:43 AM
finance.yahoo.com logoAegis Restates 'Buy' Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG)
au.finance.yahoo.com - January 11 at 9:49 PM
finance.yahoo.com logoRosetta Genomics Reports Third Quarter 2016 Financial Results
finance.yahoo.com - December 20 at 2:19 PM
reuters.com logoBRIEF-Rosetta Genomics files for resale of up to 15.5 mln of co's ordinary shares by selling stockholders
www.reuters.com - December 8 at 8:01 PM
finance.yahoo.com logoRosetta Genomics to Present at the 9th Annual LD Micro Main Event
finance.yahoo.com - December 1 at 8:15 AM
biz.yahoo.com logoQ3 2016 Rosetta Genomics Ltd Earnings Release - After Market Close
biz.yahoo.com - November 30 at 12:42 PM
streetinsider.com logoRosetta Genomics (ROSG) Prices of $5M Concurrent Registered Direct and Private Placement
www.streetinsider.com - November 24 at 10:34 AM
streetinsider.com logoRosetta Genomics (ROSG) Prices of $5M Concurrent Registered Direct and Private Placement - StreetInsider.com
www.streetinsider.com - November 23 at 7:29 PM
streetinsider.com logoRosetta Genomics (ROSG), Sheba Medical Center Enter MicroRNA-Based BiomarkerResearch Collaboration - StreetInsider.com
www.streetinsider.com - November 22 at 7:25 PM
businesswire.com logoRosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients
www.businesswire.com - November 21 at 12:37 PM

Social

Chart

Rosetta Genomics (ROSG) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff